Vaccination with CoronaVac or ChAdOx-1 altered monocyte subtypes and inflammatory status in older adults, suggesting different immune responses.
Abstract BackgroundThe older adult population was significantly affected by COVID-19 due to immunosenescence, which alters immune elements such as monocytes, impacting immune responses to pathogens and vaccination. Aging-associated systemic inflammation, or inflammaging, can further impair vaccine responses. Although important data exist, the effects of COVID-19 vaccination on monocytes and systemic inflammation in older adults are not fully understood. This study aimed to investigate the impact of COVID-19 vaccination with CoronaVac and ChAdOx-1 on monocyte subtypes and systemic inflammatory status in older adults.MethodsSixty-six older adults (74.74 ± 5.9 years) participated in this study. Blood samples were collected before and 30 days after the second dose of either CoronaVac (n = 48) or ChAdOx-1 (n = 18) to measure IgG levels for SARS-CoV-2, cytokines, and monocyte subtypes (classical, non-classical, and intermediate).ResultsBoth vaccines increased specific IgG levels post-vaccination. The ChAdOx-1 group exhibited higher IgG levels, more classical, non-classical, and intermediate monocytes, and higher IL-6/IL-10 and TNF-α/IL-10 ratios compared to CoronaVac. Conversely, CoronaVac led to higher IFN-γ post-vaccination. Both vaccines promoted distinct modulation of monocyte subtypes and inflammatory status.ConclusionBoth vaccines elicited a strong antibody response, but ChAdOx-1 demonstrated better results. Distinct changes in monocyte subtypes and inflammation were observed between the two vaccine groups.
No takes yet. Share an insight, caveat, or question.
Monteiro et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: